These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 13983190)

  • 1. [Antibodies of the Gm system in rheumatic polyarthritis (C.R.P.)].
    RUFFIE R; RUFFIE J; DUCOS J; FOURNIE A
    Rev Rhum Mal Osteoartic; 1962 Jun; 29():321-9. PubMed ID: 13983190
    [No Abstract]   [Full Text] [Related]  

  • 2. [Gm-properties in rheumatic diseases with reference to chronic progressive polyarthritis. I. Gm(a) and Gm(x) factors in rheumatic diseases].
    Neumann W; Barthel E; Tanner E; Seidel K
    Z Gesamte Inn Med; 1970 Apr; 25(7):308-11. PubMed ID: 5315625
    [No Abstract]   [Full Text] [Related]  

  • 3. [Serology in acute articular rheumatism and chronic evolutive polyarthritis].
    BOURDON JL
    Concours Med; 1962 Dec; 84():7155-68. PubMed ID: 14014443
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical relevance of antikeratin antibodies in rheumatoid arthritis and symmetric polyarthritis associated with hepatitis C infection.
    Cojocaru M; Cojocaru IM; Iacob SA
    Rom J Intern Med; 2004; 42(4):709-14. PubMed ID: 16366142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [ANTIBODIES OF THE GM SERUM SYSTEM DURING CHRONIC EVOLUTIVE POLYARTHRITIS].
    JACQUELINE F; PODLIACHOUK L; EYQUEM A
    Presse Med (1893); 1964 Sep; 72():2205-8. PubMed ID: 14192193
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
    Greiner A; Plischke H; Kellner H; Gruber R
    Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
    Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
    Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of anti-cyclic citrullinated peptides antibodies in comparison with rheumatoid factor for rheumatoid arthritis diagnosis].
    Dubrous P; Gardet V; Hugard L
    Pathol Biol (Paris); 2005 Mar; 53(2):63-7. PubMed ID: 15708648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
    Liu X; Jia R; Zhao J; Li Z
    J Rheumatol; 2009 Jun; 36(6):1136-42. PubMed ID: 19447936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated levels of IgM and IgA antibodies to Proteus mirabilis and IgM antibodies to Escherichia coli are associated with early rheumatoid factor (RF)-positive rheumatoid arthritis.
    Newkirk MM; Goldbach-Mansky R; Senior BW; Klippel J; Schumacher HR; El-Gabalawy HS
    Rheumatology (Oxford); 2005 Nov; 44(11):1433-41. PubMed ID: 16091399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis.
    Abdel-Nasser AM; Mahmoud MH; El Mansoury TM; Osman AM
    Scand J Rheumatol; 2008; 37(5):329-36. PubMed ID: 18666028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
    Vallbracht I; Helmke K
    Autoimmun Rev; 2005 Jul; 4(6):389-94. PubMed ID: 16081030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HLA-DRB1 shared epitope is not associated with antibodies against cyclic citrullinated peptide in Chinese patients with rheumatoid arthritis.
    Xue Y; Zhang J; Chen YM; Guan M; Zheng SG; Zou HJ
    Scand J Rheumatol; 2008; 37(3):183-7. PubMed ID: 18465452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies.
    Carrier N; Cossette P; Daniel C; de Brum-Fernandes A; Liang P; Ménard HA; Boire G
    Arthritis Rheum; 2009 Mar; 60(3):698-707. PubMed ID: 19248090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Incidence of Gm serum groups in primary chronic polyarthritis].
    DEICHER H; SCHUPP E
    Z Rheumaforsch; 1963 Apr; 22():69-77. PubMed ID: 14026486
    [No Abstract]   [Full Text] [Related]  

  • 16. Second generation anti-cyclic citrullinated peptide (anti-CCP2) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis.
    Grootenboer-Mignot S; Nicaise-Roland P; Delaunay C; Meyer O; Chollet-Martin S; Labarre C
    Scand J Rheumatol; 2004; 33(4):218-20. PubMed ID: 15370715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
    De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
    Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor.
    Vander Cruyssen B; Peene I; Cantaert T; Hoffman IE; De Rycke L; Veys EM; De Keyser F
    Autoimmun Rev; 2005 Sep; 4(7):468-74. PubMed ID: 16137613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The investigation of the rheumatoid factor as a diagnostic method in chronic evolutive polyarthritis. II].
    da CARLOS A GP
    Gaz Med Port; 1963; 16():15-41. PubMed ID: 14018683
    [No Abstract]   [Full Text] [Related]  

  • 20. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.